Aclaris Therapeutics, Inc

Newest shelf

S-3 of 2025-02-27. Not read yet. S-3 ↗

At the market

$100.0M

Leerink Partners, agreement of 2025-02-27. No at-the-market sales statement read from a 10-Q or 10-K. 8-K ↗

Warrants

The 10-Q filed 2026-08-06 is not read yet.

Cash

5.9 quarters

$91.6M on 2026-06-30 ÷ $15.5M a quarter of operating cash used, the average of four quarters. 10-Q ↗